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Summary
 
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a T cell costimulation receptor that delivers
inhibitory signals upon activation. Although the tyrosine-based motif (
 
165
 
YVKM) within its cy-
toplasmic tail has been shown to associate
 
 
 
in vitro
 
 
 
with Src homology 2 domain–containing ty-
rosine phosphatase (SHP-2) and phosphatidylinositol 3 kinase upon phosphorylation, the
mechanism of negative signaling remains unclear. Here, we report a new mechanism of nega-
tive signaling based on the analysis of murine T cell clones transfected with various mutants of
CTLA-4. Upon T cell activation by cross-linking with anti-CD3 and anti-CD28 antibodies,
CTLA-4 engagement inhibited both proliferation and interleukin 2 production in tyrosine
mutants as well as in wild-type CTLA-4 transfectants. Furthermore, the mutant CTLA-4 lack-
ing most of the cytoplasmic region strongly suppressed interleukin 2 production as well. These
data suggest that negative signals by CTLA-4 could be mediated through the membrane-prox-
imal region of CTLA-4 but not through the YVKM motif and that the association of CTLA-4
with SHP-2 is not required for CTLA-4–mediated suppression of T cell activation.
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TLA-4 (CTL antigen 4)
 
1
 
 is a T cell costimulation re-
ceptor and critical negative regulator of T cell activa-
tion (1–3). CTLA-4 is homologous to CD28 and shares
common ligands, CD80 and CD86, on APCs. Whereas
CD28 is constitutively expressed at high levels on the sur-
faces of both resting and activated T cells and delivers posi-
tive costimulation signals, the regulation of the cell surface
expression of CTLA-4 is more complex. CTLA-4 cannot
be detected on resting T cells, but after T cell activation,
CTLA-4 mRNA is rapidly induced and the protein be-
comes detectable on the cell surface, with a peak expression
 
48–72 h after stimulation. However, even under condi-
tions of optimal stimulation, CTLA-4 is localized pre-
dominantly within intracellular compartments and its ex-
pression level on the cell surface is only a small fraction of
that of CD28 (4, 5).
 
Functional in vitro analysis using Abs to murine CTLA-4
 
demonstrated that the addition of soluble Abs augmented
T cell responses (6). In contrast, cross-linking of CTLA-4
by immobilized Ab or secondary Abs resulted in inhibition
of T cell activation upon TCR/CD3 and CD28 stimula-
tion (7, 8). These data suggested that CTLA-4 functions as
a negative regulator of T cell activation.
Strong evidence to support the inhibitory role of CTLA-4
was provided by the analysis of mice deficient in CTLA-4
(9, 10). CTLA-4 null mutant mice exhibited a massive
lymphoproliferative disorder and died between 3 and 4 wk
of age. The majority of peripheral T cells in these mice
 
1
 
Abbreviations used in this paper:
 
 AP-2, adaptor protein complex 2;
 
 
 
CTLA-4,
 
CTL antigen 4; ERK2, extracellular signal-regulated kinase 2; MAPK,
mitogen-activated protein kinase; MBP, myelin basic protein; PI3, phos-
phatidylinositol 3; RT, reverse transcriptase; SH2, Src homology 2; SHP-2,
SH2 domain–containing tyrosine phosphatase; WT, wild-type. 
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were in an activated state and exhibited spontaneous
production of cytokines. When CTLA-4
 
2
 
/
 
2
 
 mice were
crossed with TCR-transgenic mice, the progeny did not
develop the lymphoproliferative disorder, demonstrating
that T cells from CTLA-4
 
2
 
/
 
2
 
 mice are autoreactive (11).
Recent studies have demonstrated that the cytoplasmic
tail of CTLA-4 controls its expression on the cell surface.
This cell surface expression is limited by the mechanism in
which CTLA-4 is rapidly internalized by clathrin-mediated
endocytosis and accumulates within the endosomes of acti-
vated T cells. Endocytosis of CTLA-4 is induced by the as-
sociation of its cytoplasmic tail with the medium chain
(
 
m
 
2) of the clathrin-associated adaptor protein complex 2
(AP-2), and the tyrosine-based motif containing 
 
165
 
YVKM
within the cytoplasmic tail is responsible for the binding to
 
m
 
2 (12–15). Within the tyrosine motif, Y-165 is critical for
the association with 
 
m
 
2. Furthermore, phosphorylation of
this tyrosine prevents the association with AP-2 complex,
resulting in the inhibition of endocytosis and the accumula-
tion of CTLA-4 on the cell surface (14).
It has been shown that the same tyrosine-based motif,
 
165
 
YVKM, associates with a phosphatase, Src homology
(SH)2 domain–containing tyrosine phosphatase (SHP-2)
(15, 16), and phosphatidylinositol 3 (PI3) kinase (17)
through their SH2 domains upon phosphorylation of the
tyrosine motif of CTLA-4. Using a cotransfection system
of various kinases with CTLA-4 into Cos or 293T cells,
we identified Fyn and Lck src kinases as the tyrosine kinases
responsible for phosphorylating both Y-165 and Y-182 in
the cytoplasmic tail of CTLA-4 through their direct associ-
ation with CTLA-4 (12, 18). However, in spite of the
identification of these kinases and phosphatases as CTLA-
4–associated molecules, the mechanism of negative signal-
ing of CTLA-4 remains unclear.
Here, we have identified a new mechanism of negative
signal transduction by CTLA-4. We analyzed murine nor-
mal T cell clones transfected with various forms of mutant
CTLA-4. Upon stimulation through TCR in the presence
of CD28-mediated costimulation, cross-linking with anti–
CTLA-4 mAb induced the suppression of both prolifera-
tion and IL-2 production in T cells expressing tyrosine-
substituted or cytoplasmic tail–deleted mutants of CTLA-4
as well as wild-type (WT) CTLA-4. These data demon-
strate that negative signals through CTLA-4 can be medi-
ated through the membrane-proximal region of CTLA-4
rather than the 
 
165
 
YVKM motif, probably through the as-
sociation with unidentified molecules. We also suggest here
a novel regulation of the cell surface expression of CTLA-4.
 
Materials and Methods
 
Cells and Abs.
 
A KLH-specific and I-A
 
k
 
–restricted murine
Th1-type T cell clone, 23-1-8 (19, 20), was maintained in RPMI
1640 supplemented with 10% FCS, 100 U/ml penicillin, 100
 
m
 
g/ml streptomycin, 50 
 
m
 
M 2-ME, and 5 ng/ml murine IL-2.
These T cells were stimulated with KLH (100 
 
m
 
g/ml; Calbio-
chem Corp.) and irradiated C3H/HeJ spleen cells every 3–4 wk.
Retrovirus packaging cell line BOSC23 was provided by Dr. T.
 
Kitamura (The University of Tokyo, Tokyo, Japan) and cultured
in DMEM supplemented with 10% FCS, 100 
 
m
 
g/ml 
 
l
 
-glu-
tamine, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 250 
 
m
 
g/ml
xanthine, 15 
 
m
 
g/ml hypoxanthine, 6 
 
m
 
g/ml mycophenolic acid,
and 50 
 
m
 
M 2-ME. Anti–CTLA-4 mAb (UC10.4F10.11) and
anti-CD3
 
e
 
 mAb (145-2C11) were provided by Dr. J. Bluestone
(University of Chicago, Chicago, IL). Anti-CD3
 
z
 
 mAb (H146-
968) was provided by Dr. R. Kubo (Cytel Corp., San Diego,
CA). Stimulatory anti-CD28 mAb (PV-1) was previously de-
scribed (21).
 
Retrovirus-mediated Gene Transfer into T Cell Clones.
 
Retrovi-
rus vector pMXneo (22) was provided by Dr. T. Kitamura and
used for stable transfection of WT CTLA-4 and its mutants into
T cell clone 23-1-8. To construct the retrovirus vector carrying
cDNA for WT CTLA-4, the full length cDNA (a gift from Dr.
P. Golstein, INSERM-CNRS, Marseille, France) was subcloned
into the EcoRI site of pMXneo. DNA fragments carrying point
mutations and deletions of the cytoplasmic region of CTLA-4,
Y165G (
 
165
 
Tyr-Gly), Y182G (
 
182
 
Tyr-Gly), Y165/182G (
 
165
 
Tyr-
Gly and 
 
182
 
Tyr-Gly), and 
 
D
 
CP7 (deletion of the cytoplasmic re-
gion except for the membrane-proximal 7 amino acids) were gen-
erated by PCR and also introduced into the same vector. These
retroviral constructs were transiently transfected into the packaging
cell line BOSC23 by lipofection using LipofectAMINE (GIBCO
BRL). 24 h later, the T cells prestimulated with KLH and irradi-
ated C3H/HeJ spleen cells were added to the culture and coculti-
vated for 24 h with the virus-producing BOSC23 cells. Thereaf-
ter, T cells were harvested and subjected to G418 (Geneticin;
GIBCO BRL) selection at 1 mg/ml.
 
Flow Cytometric Analysis of CTLA-4 and Cell Sorting.
 
T cells
were incubated with biotinylated anti–CTLA-4 mAb for 30 min
at 4
 
8
 
C, followed by PE–streptavidin. Flow cytometry was per-
formed using a FACScan™ flow cytometer (Becton Dickinson),
and 10
 
4
 
 cells were analyzed using the CELLQuest™ program
(Becton Dickinson).
 
Metabolic Labeling, Immunoprecipitation, and Deglycosylation.
 
T
cells (10
 
7
 
) were precultured in a methionine-free medium for 30
min, metabolically labeled with 18.5 mBq/ml [
 
35
 
S]methionine
(Tran 
 
35
 
S-Label™, ICN Pharmaceuticals, Inc.) for 3 h, harvested,
washed three times in PBS, and then lysed in 1% NP-40 lysis
buffer (1% NP-40, 50 mM Tris, 150 mM NaCl, 5 mM EDTA,
10 
 
m
 
g/ml aprotinin, 12.5 
 
m
 
g/ml antipain, 12.5 
 
m
 
g/ml chymosta-
tin, 50 
 
m
 
g/ml leupeptin, 25 
 
m
 
g/ml pepstatin A, 1 mM PMSF,
and 2 mM Na
 
3
 
VO
 
4
 
). The precleared lysates were immunopre-
cipitated with either anti–CTLA-4 or anti-CD3
 
e
 
 mAb as con-
trol. Where indicated, immunoprecipitates were treated with
 
N
 
-glycosidase F to remove N-linked oligosaccharide chains. Im-
munoprecipitated samples were resuspended with 20 
 
m
 
l of 0.1 M
2-ME/0.5% SDS, denatured by boiling, resuspended in 60 
 
m
 
l of
a buffer containing 1.5 mU 
 
N
 
-glycosidase F (Calbiochem Corp.),
167 mM Tris-Cl, pH 8.0, 13 mM 1,10-phenanthrorine, and
1.3% NP-40, incubated overnight at 37
 
8
 
C, and analyzed on 13%
SDS-PAGE. The dried gels were analyzed with a BAS-2000 im-
age analyzer (Fuji Photo Film Co.).
 
Cell Surface Biotinylation.
 
Cell surface biotinylation was per-
formed as previously described (23). Cells were solubilized in
0.5% NP-40 lysis buffer. Immunoprecipitates were treated with
 
N
 
-glycosidase F as described above and then analyzed on 14%
SDS-PAGE.
 
Proliferation Assay of T Cells.
 
For antigen stimulation, 10
 
5
 
 23-
1-8 T cells were cultured with 5 
 
3
 
 10
 
5
 
 irradiated C3H/HeJ
spleen cells and 10 
 
m
 
g/ml KLH in a 96-well flat-bottom plate for
48 h at 37
 
8
 
C in 5% CO
 
2
 
. For stimulation by FcR-dependent 
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cross-linking with anti-CD3
 
e
 
 and anti-CD28 mAbs, 2 
 
3
 
 10
 
5
 
 T
cells were cultured with 10
 
5
 
 irradiated C3H/HeJ spleen cells in
the presence of 0.1 
 
m
 
g/ml anti-CD3
 
e
 
 alone or in combination
with 1 
 
m
 
g/ml anti-CD28 mAb. In both stimulations, anti–
CTLA-4 mAb (or control anti-CD3
 
z
 
 mAb) was added at 50 
 
m
 
g/ml.
For the last 8 h of incubation, 37 kBq [
 
3
 
H]TdR (Amersham Life
Sciences) was pulsed and the uptake was measured with a liquid
scintillation counter (MicroBeta™; Pharmacia).
 
Analysis of IL-2 Production upon T Cell Activation.
 
Flat-bottom
96-well plates were sequentially coated with 0.1 
 
m
 
g/ml of anti-
CD3
 
e
 
 mAb and then with anti–CTLA-4 mAb and/or control
anti-CD3
 
z
 
 mAb to keep a constant sum concentration of mAbs
of 10 
 
m
 
g/ml. T cells were added at 10
 
5
 
/well in 200 
 
m
 
l of com-
plete RPMI 1640 in the presence or absence of 1 
 
m
 
g/ml anti-
CD28 mAb. Supernatants from triplicate cultures were collected,
and the titer of IL-2 was determined by ELISA with rIL-2 as a
standard as described previously (24). The Ab to detect IL-2 was
purchased from PharMingen.
 
Reverse Transcriptase–PCR Analysis.
 
Total RNA was ex-
tracted from stimulated or unstimulated T cells by the AGPC
(acid guanidium-phenol-chloroform) method. Reverse tran-
scriptase (RT) reaction was carried out using random hexamer
primers (Takara Biomedicals) and Superscript II (GIBCO BRL).
Twofold dilutions of the RT product were amplified with the
specific primers for IL-2, IFN-
 
g
 
, Bcl-X
 
L
 
, and 
 
b
 
-actin to ensure
that the PCR reactions were performed in a linear range.
 
Immune Complex Kinase Assay for Extracellular Signal-regulated
Kinase 2 Activity.
 
T cells were stimulated with 0.5 
 
m
 
g/ml im-
mobilized anti-CD3
 
e
 
 mAb and 10 
 
m
 
g/ml soluble anti-CD28
mAb and lysed for 30 min at 4
 
8
 
C with a lysis buffer (20 mM
Hepes, pH 7.4, 300 mM NaCl, 2 mM EGTA, 1% Triton X-100,
1 mM dithiothreitol, 20 mM 
 
b
 
-glycerophosphate, 1 mM
Na
 
3
 
VO
 
4
 
, 1 mM PMSF, 10 
 
m
 
g/ml aprotinin, 12.5 
 
m
 
g/ml anti-
pain, 12.5 
 
m
 
g/ml chymostatin, 50 
 
m
 
g/ml leupeptin, and 25 
 
m
 
g/ml
pepstatin A). Protein concentration in the lysate was determined
using the Bradford method (Bio-Rad Labs.), and 50 mg of total
protein was subjected to immunoprecipitation with polyclonal
rabbit anti–extracellular signal-regulated kinase 2 (ERK2) Ab
(Santa Cruz Biotechnology, Inc.). After the immunoprecipitates
were washed with a kinase buffer (50 mM Tris, pH 7.4, 10 mM
MgCl2, and 1 mM dithiothreitol), kinase reactions were carried
out at 308C in 30 ml of the kinase buffer containing 20 mM ATP,
5 mCi of g-[32P]ATP, and 3 mg of myelin basic protein (MBP;
Sigma Chemical Co.) as a substrate and stopped after 20 min.
Samples were resolved on 15% SDS-PAGE, and phosphorylation
of MBP was visualized and the radioactivity of each band was
quantified using a BAS-2000 image analyzer (Fuji Photo Film Co.).
ERK2 immunoblots were performed as previously described
(25). 40 mg of whole cell extracts was analyzed on 10% SDS-
PAGE and transferred onto a polyvinyl difluoride membrane
(Immobilon-P; Millipore Corp.). The membranes were blotted
with murine monoclonal anti-ERK2 (Santa Cruz Biotechnology,
Inc.), followed by a peroxidase-conjugated anti–murine IgG.
Blots were developed using the enhanced chemiluminescence
system (ECL kit; Amersham Life Sciences).
Results
Surface Expression of CTLA-4 Mutants on Resting T Cell
Clones. Although it has been shown that Y-165 of
CTLA-4 is crucial for association with AP-2 complex and
endocytosis from the cell surface in a model system using
nonlymphoid cells (12–15), the regulation of the cell sur-
face expression of CTLA-4 in normal T cells has not been
analyzed. Therefore, we examined which of the two ty-
rosines in the cytoplasmic tail of murine CTLA-4 (Y-165,
Y-182, or both) are important for the regulation of the cell
surface expression and inhibitory signals of CTLA-4 in
normal T cells. For this purpose, we generated various
forms of mutant CTLA-4 with a single tyrosine®glycine
mutation (Y165G and Y182G), double mutations (Y165/
182G), and a deletion of most of the cytoplasmic tail ex-
cept for the membrane-proximal 7 amino acids (DCP7)
(Fig. 1 A). These constructs were transfected into a murine
T cell clone, 23-1-8, by retrovirus-mediated gene transfer,
and the G418-resistant bulk population of transfected T
cells was analyzed for the surface expression of CTLA-4
(Fig. 1 B). CTLA-4 was hardly detected on the surfaces of
resting T cells transfected with the vector alone (CT T
cells). T cells transfected with the WT CTLA-4 (WT T
cells) showed only a dull expression of CTLA-4 on the cell
surface, as did T cells transfected with the Y182G mutant
CTLA-4 (Y182G T cells). In contrast, the mutation of
165Tyr®Gly (Y165G), which blocks the association with
AP-2, induced constitutively high expression of CTLA-4
on the surfaces of resting T cells. Interestingly, Y165/182G
mutants exhibited a higher expression of surface CTLA-4
than Y165G mutants, and DCP7 mutants showed even
greater expressions than Y165/182G mutants.
To test whether the significant differences in the surface
expression of CTLA-4 can be attributed to its transcrip-
tional level in these T cells, we performed Northern blot
analysis using a CTLA-4 cDNA probe. The expression
level of CTLA-4 mRNA of these WT and mutants of
CTLA-4 T cells at resting stage varied within a twofold dif-
ference (Fig. 1 C). We also examined the protein level of
CTLA-4 in T cells expressing these mutants and WT
CTLA-4. T cells were metabolically labeled with [35S]me-
thionine, and the cell lysates were immunoprecipitated
with either anti–CTLA-4 mAb or anti-CD3e mAb as con-
trol. As CTLA-4 is heavily glycosylated, simple immuno-
precipitation of the labeled CTLA-4 showed very broad
bands. Therefore, all precipitates were treated with N-gly-
cosidase F to remove all N-linked oligosaccharide chains
and then the core proteins were analyzed. As shown in Fig.
1 D, CTLA-4 protein was not precipitated in control cells.
WT and all mutant CTLA-4 cells (Y165G, Y182G, Y165/
182G, and DCP7) showed fairly similar amounts of CTLA-4
proteins. These data demonstrate that the difference in the
surface expression of CTLA-4 was not due to the different
expression level of mRNA nor protein of CTLA-4 but
rather due to translocation of CTLA-4 protein from the
cytoplasm to plasma membrane by the mutation or dele-
tion of the tyrosine motif in the cytoplasmic tail. Prelimi-
nary analysis with confocal microscopy disclosed that
CTLA-4 protein was located predominantly in the cyto-
plasmic granules in resting WT T cells, whereas the major
portion was localized on the cell surface in Y165G or
DCP7 T cells (Iida, T., C. Nakaseko, H. Ohno, and T.
Saito, manuscript in preparation).768 New Mechanism of Negative Signal Transduction by CTLA-4
The finding that Y165/182G T cells and DCP7 T cells
exhibited higher expressions of surface CTLA-4 than
Y165G T cells indicates that Y-165 is basically the tyrosine
required for regulation of the surface expression of CTLA-4
through endocytosis mediated by the clathrin–AP-2 com-
plex, but Y-182 or other regions of the cytoplasmic tail of
CTLA-4 are also involved in the regulation of the surface
expression of the molecule.
Suppression of Ag-specific Proliferation and Restoration by
Anti–CTLA-4 mAb in Mutant CTLA-4–expressing T Cells.
Previous reports demonstrated that both intact and mono-
valent fragments of CTLA-4 augmented T cell proliferation
in allogeneic MLR, whereas the same Ab inhibited prolif-
eration under the condition where FcR cross-linking was
provided (6, 7). To investigate the region in the cytoplas-
mic tail of CTLA-4 responsible for delivering negative sig-
nals, we performed functional analyses using these T cells
transfected with various mutant forms of CTLA-4. First,
we examined the effect of CTLA-4 mutants in terms of
Ag-specific proliferative response. Because 23-1-8 is a
KLH-specific T cell clone, transfectants expressing various
CTLA-4 mutants were stimulated with KLH and APCs in
the presence or absence of anti–CTLA-4 mAb. As shown
in Fig. 2 A, the proliferative response of CT T cells was not
altered by the addition of anti–CTLA-4 mAb. However,
proliferation of WT T cells was suppressed in comparison
with CT T cells. The addition of anti–CTLA-4 mAb re-
stored the response to a level almost equal to that in control
cells. In T cells with high expression of surface CTLA-4,
such as Y165G, Y165/182G, and DCP7 T cells, the sup-
pression was more significant than in WT T cells, in accor-
dance with their surface expression. For these cells, the ad-
dition of anti–CTLA-4 mAb induced dramatic restoration
of the Ag-specific response. These results suggest that mu-
tant forms of CTLA-4, with either the tyrosine mutation
or deletion of the cytoplasmic region, could deliver a nega-
Figure 1. Surface expression of transfected CTLA-4 on resting T cell clones. (A) Schematic structure of WT and mutant forms of CTLA-4. These
constructs were subcloned into the retrovirus vector pMXneo and transfected into murine Th1 cell clone 23-1-8. Black boxes represent the transmem-
brane region. EX, extracellular; TM, transmembrane; CP, cytoplasmic domains; a.a., amino acid. (B) Surface expression of CTLA-4 on resting T cell
clones transfected with control vector, WT, or CTLA-4 mutants. DCP7-low T cells were isolated from DCP7 T cells as T cells expressing low levels of
the cell surface CTLA-4 by cell sorting. T cells were stained with biotinylated anti–CTLA-4 mAb and PE–streptavidin and analyzed by FACS™. (C)
Northern blot analysis of WT and various mutant CTLA-4–transfected T cells. 10 mg of total RNA was analyzed using a full length CTLA-4 cDNA as
a probe. Quantitation of each band showed the following relative values when normalized by the vector-transfectant cells as 1: vector, 1.0; WT, 33.4;
Y165G, 55.3; Y182G, 45.8; Y165/182G, 33.8; DCP7, 26.5; and DCP7-low, 6.6. (D) Total protein levels of CTLA-4 in WT and various mutant
CTLA-4–transfected T cells. T cells expressing control vector, WT CTLA-4, mutant CTLA-4 (Y165G, Y182G, Y165/182G, DCP7), and DCP7-
low T cells were metabolically labeled with [35S]methionine and lysed in 1.0% NP-40 lysis buffer. The lysates were immunoprecipitated with anti–
CTLA-4 mAb or anti-CD3e mAb as control. Immunoprecipitates (IP) by anti–CTLA-4 mAb were treated with N-glycosidase F and then resolved on
13% SDS-PAGE. Molecular size is indicated, right (kD).769 Nakaseko et al.
tive signal for Ag-specific proliferation. Alternatively, these
molecules might inhibit the proliferation by merely com-
peting for ligand binding with CD28.
Inhibition of Costimulation-dependent Proliferation by Engage-
ment of CTLA-4 Lacking Tyrosine Motifs. To examine the
effect of cross-linking various forms of CTLA-4 with anti–
CTLA-4 mAb, T cells were stimulated with a suboptimal
dose of anti-CD3e mAb and optimal costimulation with
anti-CD28 mAb by cross-linking on FcR-bearing synge-
neic APCs. In this system, suboptimal stimulation with
anti-CD3e mAb resulted in a minimum costimulation ef-
fect by CD80/CD86 on APCs, and the addition of stimu-
latory anti-CD28 mAb greatly augmented T cell prolifera-
tion (Fig. 2 B). Under these conditions, the cross-linking of
CTLA-4 mutants with Y165G, Y165/182G, and DCP7 by
anti–CTLA-4 mAb resulted in significant inhibition of
CD3/CD28-mediated proliferation. Together with the
results in Fig. 2 A, these data strongly suggest that these
mutant forms of CTLA-4 as well as WT CTLA-4 could
transduce negative signals for proliferative response upon
engagement of TCR and CD28.
CTLA-4 Without Tyrosine Motifs Delivers a Negative Signal
for IL-2 Production. For detailed analysis of the suppressive
mechanism via CTLA-4, we used another system in which
T cells were stimulated by cross-linking of CD3, CD28,
and CTLA-4 separately with the respective specific Abs in
the absence of APCs and examined the early response by
measuring IL-2 secretion. This system made it possible to
avoid the effect of interaction between CTLA-4 and/or
CD28 and CD80 and/or CD86 on APCs and to analyze
the molecular events of CTLA-4 cross-linking both in the
early and late phases after T cell activation. To this end, T
cells expressing WT CTLA-4, Y165G, DCP7, and control
T cells were stimulated by cross-linking with a suboptimal
dose of immobilized anti-CD3e mAb in the presence or
absence of soluble stimulatory anti-CD28 mAb, and the
negative effect via CTLA-4 in IL-2 production was exam-
ined by cross-linking with immobilized anti–CTLA-4
mAb. Under this condition, the costimulatory effect of
anti-CD28 mAb was optimal for IL-2 production (Fig. 3).
In CT T cells, IL-2 secretion was inhibited by endogenous
CTLA-4 by at most 60–70% of the response upon CTLA-4
cross-linking (Fig. 3). In WT T cells, CTLA-4 cross-link-
ing resulted in significant inhibition of IL-2 production in
a dose-dependent manner (Fig. 3). In DCP7 as well as
Y165G T cells, consistent with the results of the prolifera-
tive response shown in Fig. 2, cross-linking of these
CTLA-4 mutants induced stronger inhibition of IL-2 pro-
duction than was seen in WT T cells (Fig. 3). As DCP7 T
cells express extremely high levels of mutant CTLA-4 on
their cell surfaces (severalfold higher than those expressed
by Y165G T cells), we intended to analyze the function of
DCP7 T cells with relatively low expression of the mutant
CTLA-4 on the cell surface. For this purpose, we isolated
low-expressing cells (DCP7-low) by cell sorting. The cell
surface expression of DCP7 on these cells was much lower
than that of Y165G T cells, though it was still higher than
that of WT T cells. However, when mRNA and protein
of the mutant CTLA-4 in DCP7-low T cells was analyzed,
the expression of both mRNA and protein was found to
be extremely low (Fig. 1, B and C). Analysis of the func-
tion of such DCP7-low T cells revealed that these cells
with much lower expression level of DCP7 strongly inhib-
ited IL-2 production upon CTLA-4 cross-linking (Fig. 3).
These results demonstrated that the engagement of not
only tyrosine mutants but also the cytoplasmic tail deletion
mutant of CTLA-4 could inhibit IL-2 secretion as an early
T cell response as well as proliferation as a late response.
Specific suppression of IL-2 secretion was demonstrated
by analyzing mRNA expression using a semiquantitative
RT-PCR analysis (Fig. 4). mRNAs were isolated from
various T cells after stimulation by cross-linking of CD3
and CD28 for 4 h. Similar to IL-2 secretion, ligation with
anti–CTLA-4 mAb induced strong inhibition of IL-2
Figure 2. Inhibition of proliferative response
in mutant CTLA-4–transfected T cells. (A)
Suppression of Ag-specific response in various
forms of CTLA-4–transfected T cells and resto-
ration by anti–CTLA-4 mAb. 105 T cells trans-
fected with control vector and WT or mutant
forms of CTLA-4 were stimulated with KLH
(10 mg/ml) and 5 3 105 irradiated spleen cells
in the presence of anti–CTLA-4 mAb (j) or
anti-CD3z mAb as control (h) at 50 mg/ml.
Proliferation was measured by [3H]TdR uptake.
Data are shown as mean 6 SD of triplicates. (B)
Suppression of T cell proliferation by CTLA-4
cross-linking in T cells expressing various forms
of CTLA-4 upon TCR/CD28-mediated and
FcR-dependent stimulation. 2 3 105 T cells
were stimulated with 0.1 mg/ml anti-CD3e
mAb alone (right) or in combination with 1
mg/ml soluble anti-CD28 mAb (left) in the
presence of irradiated spleen cells as FcR1 cells.
Anti–CTLA-4 mAb (j) or anti-CD3z mAb as
control (h) was added at 50 mg/ml. The data
represent the mean 6 SD of triplicates.770 New Mechanism of Negative Signal Transduction by CTLA-4
mRNA expression in WT, Y165G, and DCP7 T cells but
not in CT T cells. This inhibitory effect was not observed
for the expression of IFN-g or Bcl-XL. The expression of
the latter is known to be induced upon TCR stimulation
in the presence of CD28 costimulation (26–28). These data
support the notion that the high expression of cell surface
CTLA-4 did not physically block TCR and CD28 stimula-
tion and that the engagement of these mutant CTLA-4,
which induced high expression on the cell surface, actively
inhibited IL-2 mRNA production as early as 4 h after T
cell activation. These results also demonstrate that CTLA-4
does not merely inhibit the signal through CD28, because
the induction of CD28-dependent molecules such as Bcl-XL
were not affected by CTLA-4 cross-linking.
Suppression of ERK2 Activity through Tailless CTLA-4.
As ERKs are involved in the induction of IL-2 gene tran-
scription and it has been shown that CTLA-4 engagement
downregulates ERK activity in preactivated T cells (25),
Figure 3. Inhibition of IL-2 pro-
duction by CTLA-4 lacking tyrosine
motif upon T cell activation. 105 T
cells expressing control vector,
WT, Y165G, DCP7 CTLA-4, and
DCP7-low T cells were stimulated
with 0.1 mg/ml immobilized
anti-CD3e mAb alone (h) or in
combination with 1 mg/ml soluble
anti-CD28 mAb (s, d, j). Anti–
CTLA-4 was cocoated at 0 (s), 5
(d), and 10 (j) mg/ml. Culture su-
pernatants of triplicates were col-
lected at indicated times and murine
(m)IL-2 concentration was deter-
mined by ELISA.
Figure 4. RT-PCR analysis of cytokines and Bcl-XL. T cells trans-
fected with the control vector, WT, and various mutant forms of CTLA-4
were unstimulated or stimulated with immobilized anti-CD3e (0.1 mg/ml)
and soluble anti-CD28 (1 mg/ml) mAbs. Anti–CTLA-4 mAb or anti-
CD3z mAb as the control was cocoated at 10 mg/ml. After 4-h stimula-
tion, total RNA was extracted and RT-PCR was performed with specific
primers for IL-2, IFN-g, Bcl-XL, and b-actin.
Figure 5. Reduced ERK2 activity by cross-linking of mutant CTLA-4.
(A) Kinase activities of ERK2. T cells were stimulated with immobilized
anti-CD3e (0.5 mg/ml) and soluble anti-CD28 (10 mg/ml) mAbs. Anti–
CTLA-4 and anti-CD3z mAbs as the control were cocoated at 10 mg/ml.
Cell lysates (50 mg/lane) were immunoprecipitated with anti-ERK2 Ab.
Immune complex kinase assay was performed using MBP as a substrate
and resolved on 15% SDS-PAGE (top). The same lysates were immuno-
blotted with anti-ERK2 Ab for protein abundance (bottom). (B) Quanti-
tation of ERK2 activities. ERK2 activity in A was quantified using an
image analyzer and is represented as relative values compared with those
from unstimulated cells (with unstimulated equaling 1).771 Nakaseko et al.
D), it migrates broadly on SDS-PAGE, and we can hardly
distinguish WT from mutant CTLA-4. Therefore, we
treated the immunoprecipitates similarly to those in Fig. 1
D. In CT T cells, whereas CTLA-4 on the cell surface was
hardly detected without N-glycosidase F treatment, a small
amount of endogenous CTLA-4 of 18 kD was observed by
immunoprecipitation with anti–CTLA-4 mAb after the
treatment (Fig. 6 B, lane 4). In WT T cells, WT CTLA-4
was clearly detected by the treatment, and the amount of
WT CTLA-4 was almost 10-fold greater than that on CT
T cells (Fig. 6 B, lane 5). In DCP7 T cells, although the
mutant CTLA-4 on the cell surface was detected as a
strong band of 15 kD, the endogenous CTLA-4 of 18 kD
was hardly detected (Fig. 6 B, lane 6). These data demon-
strate that the enhancement of the surface expression of
CTLA-4 on DCP7 T cells was not caused by accumulation
of the endogenous CTLA-4 but rather by the upregulation
of the DCP7 mutant upon activation. Considering that
proliferation and IL-2 production were strongly inhibited
in DCP7 but not in WT T cells, these data demonstrate
that CTLA-4 with tyrosine mutation or tailless mutant did
transduce negative signals through the mutant CTLA-4
molecules themselves rather than by forming heterodimers
with endogenous CTLA-4.
Discussion
Recently, we and other groups demonstrated that en-
docytosis of CTLA-4 is induced by association of its cyto-
plasmic tail with the m2 subunit of clathrin-associated adap-
tor complex AP-2 (12–15). The tyrosine-based motif
containing  165YVKM within the cytoplasmic tail of CTLA-4
is responsible for the binding to m2. However, there has
been no data so far that demonstrated the same regulation
in normal T cells. In this study, we demonstrated that the
surface expression of CTLA-4 on WT CTLA-4–trans-
Figure 6. Biochemical analysis of endogenous and transfected
CTLA-4 on the cell surface of activated DCP7 CTLA-4 transfec-
tants. (A) Cell surface expression of CTLA-4 on various CTLA-4–
expressing T cells. T cells transfected with control vector, WT, Y165G, and DCP7 mutant CTLA-4 were unstimulated (top) or stimulated (bottom) with
immobilized anti-CD3e (1.0 mg/ml) and anti-CD28 (1.0 mg/ml) mAbs for 48 h. Surface expression of CTLA-4 was analyzed by FACS™ after staining
with anti–CTLA-4 mAb. (B) Biochemical analysis of the cell surface CTLA-4 on various CTLA-4–expressing T cells. Control vector (lanes 1 and 4),
WT (lanes 2 and 5), and DCP7 mutant–transfected T cells (lanes 3 and 6) were stimulated as in A, surface biotinylated, and lysed in 0.5% NP-40 lysis
buffer. The same amount of protein per sample was immunoprecipitated with anti–CTLA-4 (lanes 4–6) or a control hamster IgG (lanes 1–3). The immu-
noprecipitated samples were treated with N-glycosidase F and resolved on 14% SDS-PAGE. Closed and open arrows indicate the band of endogenous and
DCP7 mutant CTLA-4, respectively. Biotinylated proteins were visualized with streptavidin–peroxidase and enhanced chemiluminescence system.
we investigated whether mutant CTLA-4 such as DCP7
CTLA-4 has an inhibitory effect on ERK2 upon activation
of resting T cells by immune complex kinase assay. Under
the stimulation condition with suboptimal anti-CD3 and
optimal anti-CD28 mAbs as described above, the ERK2
activity was so weakly upregulated that the effect of
CTLA-4 cross-linking was hardly observed. Therefore, T
cells were stimulated by optimal CD3/CD28 stimulation,
and the effect of CTLA-4 cross-linking was examined. As
shown in Fig. 5 A, ERK2 activity was significantly upregu-
lated by the optimal CD3/CD28 costimulation within 20
min. The cross-linking of CTLA-4 significantly inhibited
ERK2 activity to about half the level of the control in
WT, Y165G, and DCP7 T cells but not in CT T cells.
These data demonstrated that WT and tailless CTLA-4
might inhibit ERK2 activity during early activation of rest-
ing T cells when expressed on the cell surface.
Responsible CTLA-4 Molecule for Suppression in CTLA-4
Mutant–expressing Cells. The inhibition of IL-2 produc-
tion in the transfectants expressing mutant CTLA-4, such
as Y165G or DCP7, is likely to be mediated through the
expressed mutant CTLA-4. However, the possibility still
remains that this suppression could be mediated through
the endogenous CTLA-4 accumulated on the cell surface
by forming heterodimers with the mutant CTLA-4. To
examine this possibility, T cells were activated with immo-
bilized anti-CD3 and anti-CD28 mAbs for 48 h, surface-
biotinylated, and immunoprecipitated with anti–CTLA-4
mAb. We analyzed the surface expression of CTLA-4 on
CT, WT, Y165G, and DCP7 T cells before and after T cell
activation (Fig. 6 A). Whereas CT T cells did not induce
the surface expression of CTLA-4, WT T cells slightly en-
hanced the expression upon activation. The enhancement
of the surface expression of CTLA-4 upon stimulation was
also observed in Y165G and DCP7 mutant CTLA-4 trans-
fectants. Because CTLA-4 is heavily glycosylated (Fig. 1772 New Mechanism of Negative Signal Transduction by CTLA-4
fected T cells was dull at the resting stage and that CTLA-4
was predominantly localized in the cytoplasm rather than
on the cell surface. Whereas the expression of CTLA-4 on
T cells transfected with the Y182G mutant was similar to
WT CTLA-4 T cells, Y165G mutants exhibited a constitu-
tively high expression of the cell surface CTLA-4, suggest-
ing that Y-165 is critical for the regulation of surface ex-
pression of CTLA-4 in normal T cells.
In addition, we found that the surface expression of
Y165/182G and DCP7 mutant CTLA-4 at the resting
stage was higher than that of the Y165G mutant. Further-
more, the surface expression of these mutants as well as
WT CTLA-4 was enhanced upon activation. These data
strongly suggest that Y-182 and/or other regions of the cy-
toplasmic tail are also involved in the regulation of the sur-
face expression of CTLA-4. The mechanism of transport of
CTLA-4 from intracellular endosomal pool to the plasma
membrane might contribute to this regulation along with
clathrin-associated endocytic machinery.
Although functional analyses of CTLA-4 engagement
have been extensively performed in vivo and in vitro, very
little is known about the signaling events resulting from li-
gation of CTLA-4. PI3 kinase has been shown to associate
with the cytoplasmic tail of CTLA-4 upon receptor liga-
tion (17). The same kinase also binds to the cytoplasmic tail
of CD28 (29, 30), and then the suppressive effect of
CTLA-4 can only be explained by sequestering PI3 kinase
by the high expression of CTLA-4. However, the fact that
the expression level of CD28 is much higher than that of
CTLA-4 suggests that this possibility is unlikely. It has also
been suggested that the role of PI3 kinase binding to
CTLA-4 may regulate the transport of molecules from in-
tracellular vesicles to the cell surface (4, 5, 29). Other in-
vestigators have reported that phosphatase SHP-2 associates
with the same tyrosine of CTLA-4 upon activation and can
be coimmunoprecipitated with phosphorylated CTLA-4
peptide (15, 16). Such CTLA-4 immunoprecipitates could
dephosphorylate p52Shc in vitro. Furthermore, it has been
shown that the kinases Fyn, Lck, and ZAP-70 were acti-
vated and other proteins, including CD3z and p52Shc, were
constitutively hyperphosphorylated in T cells from CTLA-4–
deficient mice. However, these findings might be attrib-
uted to the hyperactive status of T cells in CTLA-4–defi-
cient mice rather than being a direct consequence of the
lack of CTLA-4 (9, 10). Frearson et al. reported that SHP-2
plays a critical role in connecting TCR to the Ras/MAPK
(mitogen-activated protein kinase) pathway in TCR stimu-
lation of Jurkat T cells (31), in which the expression of
mutant SHP-2 significantly inhibited TCR-induced activa-
tion of ERK2 but had no effect on CD3z tyrosine phos-
phorylation or TCR-elicited Ca21 mobilization. Taken to-
gether with the observation in signaling through several
receptor tyrosine kinases that SHP-2 has been demon-
strated to stimulate rather than inhibit growth factor–
induced Ras/MAPK activation (32, 33), these reports sug-
gest that SHP-2 plays a positive role in TCR stimulation
rather than serving as a negative regulator of CTLA-4 en-
gagement.
In this study, we identified a new mechanism of negative
signal transduction by CTLA-4. We analyzed CTLA-
4–transfected T cells by cross-linking CD3, CD28, and
CTLA-4 separately with specific Abs to avoid the com-
plexity derived from the T cell–APC interaction. One of
the mechanisms of suppression by CTLA-4 has been
thought to be the competition of the ligand CD80/86 with
CD28 (34, 35). In our system, we proved that ligand-inde-
pendent cross-linking of CTLA-4 induces suppression. En-
gagement of mutant forms of CTLA-4 with Y-165 substi-
tution or complete deletion resulted in strong inhibition of
IL-2 production upon CD3/CD28 costimulation. Under
these conditions, IL-2 mRNA expression was significantly
suppressed by CTLA-4 cross-linking just 4 h after stimula-
tion. If these mutants were functionally inactive and served
as dominant negative mutants of CTLA-4, their engagement
would augment proliferation or IL-2 secretion. However,
these mutants lacking the tyrosine motif did not serve as
dominant negative forms for endogenous CTLA-4. Another
argument for the strong inhibition of T cell activation by
CTLA-4 mutants might be explained if the cross-linking of
highly expressed CTLA-4 could physically interfere with
the CD3/CD28 stimulation on the cell surface. However,
the observation that the induction of IFN-g or Bcl-XL
mRNA expression was not inhibited by CTLA-4 cross-
linking in the same T cells ruled out this possibility. Thus,
we demonstrated that CTLA-4 cross-linking inhibits IL-2
production and proliferation induced by CD3/CD28 stim-
ulation even in the absence of its tyrosine motif within the
cytoplasmic tail. Therefore, in contrast to the current model
for an inhibitory mechanism through SHP-2 activation,
our results clearly show that the association of CTLA-4
with PI3 kinase and SHP-2 is not required for CTLA-4–
mediated suppression of T cell activation, although it is still
possible that the tyrosine motif may also partly contribute
to CTLA-4–induced inhibition.
Recently, CTLA-4 was found to associate with the
CD3z chain in primary T cells (36). It has been suggested
that the interaction of CTLA-4 and CD3z recruits SHP-2
into the complex that induces CD3z dephosphorylation.
However, these analyses showed only the effect on z phos-
phorylation; the functional consequence has not yet been
determined. Considering that this analysis demonstrated
that the association depends on the cytoplasmic tail of
CTLA-4 and the tailless CTLA-4 did not associate with
CD3z (36), the inhibition through DCP7 CTLA-4 in our
study could be induced by a different mechanism than
CTLA-4–CD3z interaction.
Upon CD3/CD28 stimulation, the surface CTLA-4 ex-
pression on Y165G or DCP7 mutant T cells was signifi-
cantly increased. Analysis of CTLA-4 species on the sur-
faces of DCP7 T cells demonstrated that the mutant CTLA-4
did not form heterodimers with endogenous CTLA-4 on
the cell surface, ruling out the possibility that endogenous
CTLA-4 accumulated on the cell surface upon activation
and delivered a negative signal. Inhibition of both prolifer-
ation and IL-2 production in WT T cells was much less
than that in DCP7 mutant T cells. These results prove that773 Nakaseko et al.
cross-linking of the DCP7 mutant did deliver an inhibitory
signal. Heterodimers between endogenous CTLA-4 and
the mutant were not detected; if there are any, they are
probably endocytosed by internalization machinery.
The target molecule of inhibition by CTLA-4 has not
yet been identified. As CTLA-4 inhibits CD28-dependent
TCR activation, the target molecules may be related to
CD28 signals. Both ERKs and Jun NH2-terminal kinases
(JNKs) have been reported to be involved in the induction
of IL-2 gene transcription, and it has been reported that
CTLA-4 engagement downregulates these MAPKs (25).
We investigated whether Y165G or DCP7 mutant CTLA-4
has an inhibitory effect on ERK2 upon activation of resting
T cells. However, under the condition of suboptimal
CD3/optimal CD28 stimulation, where IL-2 secretion was
maximally inhibited by CTLA-4, the ERK2 activity was
only weakly upregulated and the effect of CTLA-4 cross-
linking was not clearly observed. When we examined
ERK2 activity upon optimal CD3/CD28 stimulation, it
was upregulated in T cells and was reduced to an approxi-
mately half level by CTLA-4 cross-linking, even in Y165G
or DCP7 mutant CTLA-4 as well as WT CTLA-4–trans-
fected cells. In addition, the suppression of JNK was not
clearly observed in our system (data not shown). Taken to-
gether with the results of Frearson et al. (31), the inhibition
of ERK2 upon CTLA-4 engagement is not mediated by
SHP-2. Although CTLA-4 may suppress more efficiently
upon stimulation with suboptimal CD3/optimal CD28
stimulation under physiological conditions, it is difficult to
conclude from these results that the suppression of the early
event of ERK2 upregulation upon TCR/CD3 stimulation
is the primary cause of CTLA-4–mediated inhibition of IL-2
production. Further analysis will be required.
Collectively, these data suggest that negative signals by
CTLA-4 for IL-2 production and proliferation could be
mediated through the membrane-proximal region of
CTLA-4 rather than the 165YVKM motif. The suppression
is probably mediated through the association with as yet
unidentified transmembrane or intracellular molecules, or,
alternatively, is due to the proper positioning of the extra-
cellular region upon T cell activation. The recent finding
that CD28 mediates reorganization of TCR signaling ma-
chinery to rafts (37) may suggest that CTLA-4 inhibits such
CD28 function. The tyrosine motif plays a role in regulat-
ing the surface expression of CTLA-4 through clathrin-
mediated endocytosis and, in addition, might have other
unknown signaling functions.
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